FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer
Open Access
- 17 September 2024
- journal article
- case report
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-7
Abstract
Genomic alterations in fibroblast growth factor receptor (FGFR) genes are present in a small number of metastatic pancreatic ductal adenocarcinomas (PDAC) and may represent an emerging subgroup of patients likely to benefit from FGFR targeted therapies. Here we present four FGFR2 fusion-positive metastatic PDAC patients who exhibited durable responses or disease control to FGFR kinase inhibitors. Utilizing our custom FGFR focused cell-free DNA assay, FGFR-Dx, we serially monitored variant allele fractions of FGFR2 fusions during FGFR inhibitor treatment and observed dynamic changes correlating with clinical responses. Genomic analysis of 30,229 comprehensively profiled pancreatic cancers revealed FGFR1-3 fusions in 245 cases, an incidence of 0.81%. FGFR fusions were generally mutually exclusive from other known oncogenes. Our findings provide clinical evidence for identifying and treating FGFR2 fusion-positive PDAC patients with FGFR targeted therapy.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (UH3 CA262220)
- Gateway for Cancer Research (AWD-110943, AWD-114129)
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (T32 TR004543)
This publication has 33 references indexed in Scilit:
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive CholangiocarcinomaCancer Discovery, 2017
- VarDict: a novel and versatile variant caller for next-generation sequencing in cancer researchNucleic Acids Research, 2016
- Manta: rapid detection of structural variants and indels for germline and cancer sequencing applicationsBioinformatics, 2015
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPLOS ONE, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010
- The clinical utility of the CA 19-9 tumor-associated antigen.1990